Drug intelligence / Profile preview

pemirolast potassium

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Ophthalmic

Overview

Pemirolast potassium is a mast cell stabilizer indicated for the prevention of itching associated with allergic conjunctivitis. It acts by inhibiting the antigen-induced release of inflammatory mediators, including histamine and leukotrienes, from mast cells. Additionally, it has been shown to inhibit the chemotaxis of eosinophils into ocular tissue and prevent their activation. Originally developed by Mitsubishi Tanabe Pharma, the drug is marketed in China by Shenzhen Relin Medicine under the brand name Huiming. It is typically administered as a topical ophthalmic solution.

Brand names: HuimingAlamast
Other names: pemirolastpemirolastumpemirolast potassium

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on pemirolast potassium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pemirolast potassium.

Explore the full profile